HealthyCOMPNCT03455010
Dose-Response Relationship of Ambulatory Load and Cartilage - Pilot Study
A study testing Increased load and Reduced load in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The research question is if there is a dose-response relationship between blood biomarkers for articular cartilage and the magnitude of physiological load. To investigate this load induced biomarker change, the participants will complete a 30-minute walking test under three loading conditions: A: 80%, B: 100% C: 120%… Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Increased load and Reduced load
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteSwitzerland
- Study dates
- 5 Jul 2017to 31 Jul 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age between 18 and 30 years
- being physically active (> 2/week)
- body mass index (BMI) <30 kg/m2
Who cannot join
- previous knee injury
- neuromuscular condition affecting gait
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Basel
Basel, Canton of Basel-City, 4031
About this study
The research question is if there is a dose-response relationship between blood biomarkers for articular cartilage and the magnitude of physiological load. To investigate this load induced biomarker change, the participants will complete a 30-minute walking test under three loading conditions: A: 80%, B: 100% C: 120% of their respective bodyweight (Fig. 1).
The main biomarker we are interested in is called cartilage oligomeric matrix protein (COMP). Serum COMP levels are increased immediately after 30-min running but there is no dose-response relationship shown yet.
Read the detailed description
The current state of research in the field and of our own research clearly shows that the in vivo mechanobiology of articular cartilage is poorly understood. Previous results of changes in cartilage biomarker concentrations after ambulatory exercise raise the following question:
Do load-induced changes in blood biomarkers for articular cartilage (COMP) depend on the physiological load magnitude? To generate initial data for answering this question, we will establish the experimental framework to systematically study the in vivo mechanobiology of human articular cartilage to address the following aims.
- To obtain pilot data for investigating the in vivo dose-response relationship of weight-bearing and blood levels of mechanosensitive biomarker of articular cartilage using controlled load- bearing as experimental paradigm.
- To provide pilot data for comparing ambulatory biomechanics between the controlled load- bearing conditions.
The experimental setting consists of a 30-minutes walking stress test under three loading conditions: A: 80 %, B: 100% and C: 120% bodyweight. Unloading will be achieved through an unloading system and additional loading with an adjustable weight vest. Before and after the walking stress test, venous blood samples will be taken at five time points. The biomarker concentration is measured with a commercial available enzyme-linked immunosorbent assay (ELISA).
Hypothesis Our working hypothesis is that there is a dose-response relationship between the temporarily increased or decreased load and the load-induced change in COMP level in the blood serum. We assume that serum COMP concentration increases with increasing accumulated load on the knee cartilage simulated through the three different loading conditions.
Design The design of the pilot study is a controlled multimodal data collection (biological, biomechanical) with block randomization. Specifically, we will collect blood samples and biomechanical (kinematic and pressure) data. We will determine the relationship between the serum blood concentration and the biomechanical data.
Because this is a cross-over study, all participants will perform the same three walking stress tests but in random order. Each participant of the study will be tested for 2.5 hours on 3 separate days.
Method In this experiment, we will test 24 healthy participants (12 male, 12 female) on 3 test days under three different loading conditions in a randomized block design. On each test day, participants will complete walking stress test for 30-minutes with A: 80%, B: 100% and C: 120% of their bodyweight. Through the modified bodyweight we generate higher or lower forces on the knee cartilage, which should affect the COMP concentration in the blood serum.
To measure the change in serum COMP concentration, blood samples will be taken at five time points before and after the walking stress test. The blood samples are taken by a study nurse. For the venipuncture, a thin, sterile, disposable vein catheter is placed in the antecubital vein. The catheter stays in the vein for the entire 2.5 hours of the experiment. Blood samples will be collected and allowed to clot for 30-minutes. Serum will be separated and frozen in aliquots to -20°C within 1 hour of collection and then transferred for storage at -80°C until assayed. Serum biomarker concentrations will be determined using commercial ELISAs.
- Conditions
- Healthy
- Being tested
- Increased load, Reduced load
- Keywords
- Ambulatory load, Biomarker, Articular cartilage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Increased loadOther
Participants walk with 120% body weight achieved with a weight vest
Reduced loadOther
Participants walk with 80% body weight achieved by a dynamic unloading system
| Study group | Role | What they receive |
|---|---|---|
| Normal load | No intervention | Healthy subjects walking for 30 minutes on a treadmill with normal body weight |
| Increased load | Experimental | Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight Receives: Other: Increased load |
| Reduced load | Experimental | Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight Receives: Other: Reduced load |
What is being measured
The primary outcome is the main question the study is designed to answer.
Load-induced serum Cartilage Oligomeric Matrix Protein concentration
Change in serum concentration during 30-minute walking exercise determined by commercial ELISA 30 min before to 2 hours after 30-minute walking exercise
Measured: 3 hours
Secondary outcomes (2)
Overall ground reaction force impulse
Area under the ground reaction curve multiplied by number of steps taken during 30-minute walking exercise
Measured: 30 minutes
Dynamic range of motion lower extremity joints
Min to max joint angles (ankle, knee, hip) measured using RehaGait (inertial measurement units)
Measured: 30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2018
- Study start5 Jul 2017
- Primary completion30 Sep 2017
- Study completion31 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Controlled multimodal data collection (biological, biomechanical) with block randomization.
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- University of Erlangen-Nürnberg
- Responsible party
- Sponsor
- Investigators
- Annegret Muendermann, PhD, Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03455010
- Sponsor's protocol ID
- 2017-01006
- Other IDs
- 2017
- Acronym
- COMP
- Status last verified
- Sep 2019
- First submitted
- 27 Feb 2018
- Last updated
- 18 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-Response Relationship of Ambulatory Load and Cartilage - Pilot Study
- ClinicalTrials.gov ID
- NCT03455010
- Acronym / sponsor ID
- COMP / 2017-01006
- Conditions
- Healthy
- Keywords
- Ambulatory load, Biomarker, Articular cartilage
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Collaborators
- University of Erlangen-Nürnberg
- Study start
- 5 Jul 2017 (actual)
- Primary completion
- 30 Sep 2017 (actual)
- Study completion
- 31 Jul 2019 (actual)
- First posted
- 6 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The research question is if there is a dose-response relationship between blood biomarkers for articular cartilage and the magnitude of physiological load. To investigate this load induced biomarker change, the participants will complete a 30-minute walking test under three loading conditions: A: 80%, B: 100% C: 120% of their respective bodyweight (Fig. 1).
The main biomarker we are interested in is called cartilage oligomeric matrix protein (COMP). Serum COMP levels are increased immediately after 30-min running but there is no dose-response relationship shown yet.
Detailed description
The current state of research in the field and of our own research clearly shows that the in vivo mechanobiology of articular cartilage is poorly understood. Previous results of changes in cartilage biomarker concentrations after ambulatory exercise raise the following question:
Do load-induced changes in blood biomarkers for articular cartilage (COMP) depend on the physiological load magnitude? To generate initial data for answering this question, we will establish the experimental framework to systematically study the in vivo mechanobiology of human articular cartilage to address the following aims.
- To obtain pilot data for investigating the in vivo dose-response relationship of weight-bearing and blood levels of mechanosensitive biomarker of articular cartilage using controlled load- bearing as experimental paradigm.
- To provide pilot data for comparing ambulatory biomechanics between the controlled load- bearing conditions.
The experimental setting consists of a 30-minutes walking stress test under three loading conditions: A: 80 %, B: 100% and C: 120% bodyweight. Unloading will be achieved through an unloading system and additional loading with an adjustable weight vest. Before and after the walking stress test, venous blood samples will be taken at five time points. The biomarker concentration is measured with a commercial available enzyme-linked immunosorbent assay (ELISA).
Hypothesis Our working hypothesis is that there is a dose-response relationship between the temporarily increased or decreased load and the load-induced change in COMP level in the blood serum. We assume that serum COMP concentration increases with increasing accumulated load on the knee cartilage simulated through the three different loading conditions.
Design The design of the pilot study is a controlled multimodal data collection (biological, biomechanical) with block randomization. Specifically, we will collect blood samples and biomechanical (kinematic and pressure) data. We will determine the relationship between the serum blood concentration and the biomechanical data.
Because this is a cross-over study, all participants will perform the same three walking stress tests but in random order. Each participant of the study will be tested for 2.5 hours on 3 separate days.
Method In this experiment, we will test 24 healthy participants (12 male, 12 female) on 3 test days under three different loading conditions in a randomized block design. On each test day, participants will complete walking stress test for 30-minutes with A: 80%, B: 100% and C: 120% of their bodyweight. Through the modified bodyweight we generate higher or lower forces on the knee cartilage, which should affect the COMP concentration in the blood serum.
To measure the change in serum COMP concentration, blood samples will be taken at five time points before and after the walking stress test. The blood samples are taken by a study nurse. For the venipuncture, a thin, sterile, disposable vein catheter is placed in the antecubital vein. The catheter stays in the vein for the entire 2.5 hours of the experiment. Blood samples will be collected and allowed to clot for 30-minutes. Serum will be separated and frozen in aliquots to -20°C within 1 hour of collection and then transferred for storage at -80°C until assayed. Serum biomarker concentrations will be determined using commercial ELISAs.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Controlled multimodal data collection (biological, biomechanical) with block randomization.
| Arm | Type | Receives |
|---|---|---|
| Normal load | No intervention | –Healthy subjects walking for 30 minutes on a treadmill with normal body weight |
| Increased load | Experimental | Other: Increased loadHealthy subjects walking for 30 minutes on a treadmill with 20% additional body weight |
| Reduced load | Experimental | Other: Reduced loadHealthy subjects walking for 30 minutes on a treadmill with 20% lower body weight |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age between 18 and 30 years
- being physically active (> 2/week)
- body mass index (BMI) <30 kg/m2
Key exclusion criteria (2 listed)
- previous knee injury
- neuromuscular condition affecting gait
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Increased loadParticipants walk with 120% body weight achieved with a weight vest | Other | Increased load |
| Reduced loadParticipants walk with 80% body weight achieved by a dynamic unloading system | Other | Reduced load |
Primary outcome
Load-induced serum Cartilage Oligomeric Matrix Protein concentration
Time frame: 3 hours
Change in serum concentration during 30-minute walking exercise determined by commercial ELISA 30 min before to 2 hours after 30-minute walking exercise
2 secondary outcomes
Overall ground reaction force impulse
Time frame: 30 minutes
Dynamic range of motion lower extremity joints
Time frame: 30 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Annegret Muendermann, PhD principal investigator
University Hospital, Basel, Switzerland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Increased load and Reduced load in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Load-induced serum Cartilage Oligomeric Matrix Protein concentration (time frame: 3 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2019.